Our study demonstrated that a combined CDO1 and CELF4 DNA methylation (epiHERA®) assay has a high accuracy (97.3%), sensitivity (84.1%), and specificity (98.8%) in diagnosing endometrial cancer. This evidence concerns the gene CDO1 and endometrial cancer.